elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
Pricing
Log in
Sign up
Home
/
Subjects
/
Abiraterone
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Abiraterone
RIS
0.005
(Research Intensity Score)
Papers
463
Top papers
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
2022 · 268 citations
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
2025 · 52 citations
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
2025 · 49 citations
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
2025 · 44 citations
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
2024 · 60 citations
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
2019 · 671 citations
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
2017 · 1786 citations
Recent Advances in the Management of Metastatic Prostate Cancer
2021 · 146 citations
Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
2023 · 72 citations
Newest papers
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
2026 · 5 citations
Evolution of AR and Non- AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
2026 · 2 citations
Price transparency & out-of-pocket payments for medications: Implications of associated delivery fees in the United States
2026 · 1 citations
Empirical-Null Calibration Challenges Comparative CNS Safety Signals for Androgen-Receptor Pathway Inhibitors: A FAERS Re-Analysis
2026
Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone
2026 · 1 citations
Fracture risk and survival outcomes of radium-223 therapy for bone metastases in mCRPC and the modulatory role of bone-protective therapy: a systematic review and meta-analysis
2026 · 1 citations
Personalized therapy in metastatic hormone-sensitive prostate cancer: a 2026 update on navigating therapeutic complexity
2026
Direct Androgen Receptor Antagonism Enhances Therapeutic PSMA Radioligand Uptake in Prostate Cancer Models
2026
Data from <sup>131</sup>I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study
2026
Browse all papers →
Abiraterone's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Abiraterone's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link